At the end of the latest market close, Cytokinetics Incorporated (CYTK) was valued at $31.48. In that particular session, Stock kicked-off at the price of $31.77 while reaching the peak value of $33.43 and lowest value recorded on the day was $30.79. The stock current value is $33.10.Recently in News on September 12, 2021, Cytokinetics Announces Results From REDWOOD-HCM and GALACTIC-HF Presented in Late Breaking Clinical Trial Session at the HFSA Annual Scientific Meeting. Full Results from REDWOOD-HCM Demonstrate Improvements in Biomarkers and Heart Failure Symptoms in Patients with Obstructive Hypertrophic Cardiomyopathy Treated with Aficamten Supporting Progression to Phase 3 Clinical Trial. You can read further details here
Cytokinetics Incorporated had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $34.32 on 08/30/21, with the lowest value was $17.72 for the same time period, recorded on 07/14/21.
Cytokinetics Incorporated (CYTK) full year performance was 43.91%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Cytokinetics Incorporated shares are logging -3.55% during the 52-week period from high price, and 125.02% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $14.71 and $34.32.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1343002 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Cytokinetics Incorporated (CYTK) recorded performance in the market was 59.29%, having the revenues showcasing 48.56% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 2.81B, as it employees total of 184 workers.
Specialists analysis on Cytokinetics Incorporated (CYTK)
During the last month, 7 analysts gave the Cytokinetics Incorporated a BUY rating, 2 of the polled analysts branded the stock as an OVERWEIGHT, 1 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 25.90, with a change in the price was noted +7.10. In a similar fashion, Cytokinetics Incorporated posted a movement of +27.31% for the period of last 100 days, recording 1,474,419 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for CYTK is recording 8.44 at the time of this writing. In addition, long term Debt to Equity ratio is set at 7.75.
Trends and Technical analysis: Cytokinetics Incorporated (CYTK)
Raw Stochastic average of Cytokinetics Incorporated in the period of last 50 days is set at 92.65%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 76.63%. In the last 20 days, the company’s Stochastic %K was 41.55% and its Stochastic %D was recorded 23.82%.
Now, considering the stocks previous presentation, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 59.29%. Additionally, trading for the stock in the period of the last six months notably improved by 38.61%, alongside a boost of 43.91% for the period of the last 12 months. The shares 6.60% in the 7-day charts and went up by 2.95% in the period of the last 30 days. Common stock shares were driven by 48.56% during last recorded quarter.